CA
NZ
UK
AU
IND
US
…
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aclaris Therapeutics Inc is a clinical-stage company developing therapies for dermatologic and immune-mediated conditions through a pipeline of topical and systemic candidates. Long-term growth may be driven by clinical trial progress, regulatory approvals and strategic partnerships that could support commercialization in areas with unmet need.
Key investment risks include clinical and regulatory setbacks, limited financial resources that may necessitate dilutive financing or partnerships, and intense competition in dermatology markets.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -64.92M | -132.06M | -88.85M | -86.91M | -90.86M |
| Net income | -64.92M | -132.06M | -88.48M | -88.66M | -114.28M |
| Selling general administrative | 21.97M | 22.20M | 31.10M | 25.13M | 23.62M |
| Gross profit | 5.74M | 15.93M | 13.17M | 17.79M | 2.05M |
| Reconciled depreciation | 0.45M | 0.81M | 0.86M | 0.80M | 0.92M |
| Ebit | -64.92M | -52.53M | -116.31M | -85.15M | -65.38M |
| Ebitda | -64.47M | -51.72M | -115.45M | -79.66M | -41.05M |
| Depreciation and amortization | 0.45M | 0.81M | 0.86M | 5.50M | 24.34M |
| Non operating income net other | - | - | - | 2.95M | -1.14M |
| Operating income | -76.38M | -141.93M | -97.36M | -85.15M | -65.38M |
| Other operating expenses | 84.20M | 160.65M | 128.61M | 114.91M | 72.14M |
| Interest expense | - | - | - | 4.70M | 23.42M |
| Tax provision | - | 0.00M | -0.37M | 0.00M | 0.00M |
| Interest income | 7.64M | 7.95M | - | - | - |
| Net interest income | 7.64M | 7.95M | - | - | - |
| Income tax expense | - | - | -0.37M | 1.75M | 23.42M |
| Total revenue | 7.83M | 18.72M | 31.25M | 29.75M | 6.76M |
| Total operating expenses | 82.11M | 157.86M | 110.53M | 102.95M | 67.43M |
| Cost of revenue | 2.09M | 2.79M | 18.08M | 11.96M | 4.71M |
| Total other income expense net | 11.45M | 9.87M | 8.51M | -1.75M | -25.48M |
| Net income from continuing ops | -64.92M | -132.06M | -88.48M | -86.91M | -90.86M |
| Net income applicable to common shares | - | - | - | -86.91M | -90.86M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 160.46M | 220.33M | 197.41M | 254.60M | 251.21M |
| Intangible assets | - | - | 0.27M | 6.97M | 7.05M |
| Other current assets | 55.05M | 12.04M | 9.45M | 13.49M | 12.99M |
| Total liab | 57.38M | 64.77M | 40.23M | 56.98M | 53.87M |
| Total stockholder equity | 103.08M | 155.55M | 157.18M | 197.62M | 197.34M |
| Deferred long term liab | - | - | - | 0.37M | 0.37M |
| Other current liab | 14.94M | 23.02M | 2.20M | 10.90M | 2.20M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -967.78M | -902.86M | -770.80M | -682.32M | -595.41M |
| Other liab | - | - | - | 33.47M | 28.77M |
| Other assets | - | - | - | 1.74M | 251.21M |
| Cash | 19.96M | 24.57M | 39.88M | 45.28M | 27.35M |
| Total current liabilities | 28.64M | 31.60M | 30.95M | 21.94M | 22.93M |
| Current deferred revenue | - | 3.89M | 19.45M | - | 10.05M |
| Net debt | -17.84M | -24.57M | -39.45M | -44.59M | -26.66M |
| Short term debt | 0.55M | 0.96M | 0.43M | 0.68M | 0.69M |
| Short long term debt total | 2.12M | 2.60M | 0.43M | 0.68M | 0.69M |
| Other stockholder equity | 1070.26M | 1058.32M | 928.08M | 880.83M | 792.97M |
| Property plant equipment | - | - | - | 1.10M | 1.33M |
| Total current assets | 151.36M | 125.95M | 128.86M | 231.55M | 205.03M |
| Long term investments | 60.61M | 90.30M | 62.77M | 12.24M | 34.24M |
| Net tangible assets | - | - | - | 190.65M | 190.29M |
| Short term investments | 70.79M | 89.02M | 79.23M | 172.29M | 164.06M |
| Net receivables | 5.57M | 0.32M | 0.30M | 0.48M | 0.62M |
| Inventory | - | - | - | -12.24M | -34.24M |
| Accounts payable | 13.16M | 4.69M | 8.88M | 10.35M | 9.98M |
| Accumulated other comprehensive income | 0.61M | 0.10M | -0.11M | -0.90M | -0.22M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -682.32M | -595.41M |
| Non currrent assets other | -51.52M | 3.07M | 1.74M | 2.73M | 3.55M |
| Non current assets total | 9.10M | 94.38M | 68.55M | 23.05M | 46.18M |
| Capital lease obligations | - | - | 0.43M | 0.68M | 0.69M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 49.31M | -69.77M | 46.22M | 12.63M | -167.32M |
| Change to liabilities | - | - | - | 0.96M | 4.12M |
| Total cashflows from investing activities | 48.37M | -69.77M | 46.22M | 12.63M | -167.63M |
| Net borrowings | - | - | 0.00M | - | -11.48M |
| Total cash from financing activities | -5.86M | 74.54M | 26.71M | 72.87M | 225.05M |
| Change to operating activities | - | - | - | -1.70M | -5.15M |
| Net income | -64.92M | -132.06M | -88.48M | -86.91M | -90.86M |
| Change in cash | -4.61M | -15.31M | -5.40M | 17.93M | 5.29M |
| Begin period cash flow | 24.57M | 39.88M | 45.28M | 27.35M | 22.06M |
| End period cash flow | 19.96M | 24.57M | 39.88M | 45.28M | 27.35M |
| Total cash from operating activities | -47.11M | -20.07M | -78.33M | -67.57M | -52.13M |
| Issuance of capital stock | 0.00M | 74.91M | 26.71M | 72.74M | 238.20M |
| Depreciation | 0.45M | 0.81M | 0.86M | 0.80M | 0.92M |
| Other cashflows from investing activities | -0.83M | -35.81M | - | - | - |
| Change to account receivables | 6.14M | -0.02M | 0.19M | 0.14M | 0.15M |
| Sale purchase of stock | - | - | -0.10M | 72.90M | 239.66M |
| Other cashflows from financing activities | -5.86M | -0.38M | -0.01M | 0.12M | -1.67M |
| Change to netincome | - | - | - | 19.74M | 39.15M |
| Capital expenditures | 0.11M | 0.12M | 1.31M | 0.60M | 0.31M |
| Change receivables | - | - | - | 0.14M | 0.15M |
| Cash flows other operating | - | - | - | -2.29M | -5.62M |
| Cash and cash equivalents changes | - | - | - | 17.93M | 5.29M |
| Change in working capital | 2.67M | 10.92M | 9.39M | -1.20M | -1.34M |
| Stock based compensation | 12.38M | 10.86M | 20.54M | 15.04M | 14.06M |
| Other non cash items | 2.30M | 89.41M | -20.27M | 4.70M | 24.34M |
| Free cash flow | -47.11M | -20.20M | -79.63M | -68.17M | -52.44M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics Inc |
- -% |
3.79 | - | - | 64.52 | 4.91 | 53.08 | 0.28 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Dr. Neal S. Walker D.O. | Co-Founder, CEO & Director | 1970 |
| Mr. Frank Ruffo | Co-Founder, CFO & Treasurer | 1966 |
| Dr. Joseph Monahan | Chief Scientific Officer | NA |
| Dr. Douglas J. Manion Frcp(C), M.D. | Pres & COO | 1961 |
| Mr. Robert A. Doody Jr. | VP of Investor Relations | NA |
| Mr. Matthew Rothman J.D. | Gen. Counsel & Corp. Sec. | NA |
| Dr. Jon Jacobsen Ph.D. | Sr. VP of Chemistry | NA |
| Dr. Paul S. Changelian Ph.D. | Sr. VP of Biology | NA |
| Mr. James Loerop | Chief Bus. Officer | 1965 |
| Dr. Ian Anderson Ph.D. | Exec. VP of Translational R&D | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...